Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chun-Jen Liu

Showing results (301-310 of 367) with videos related to

Pageof 37
Sort By:
Journal of the Formosan Medical Association = Taiwan Yi Zhi|December 12, 2018
Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutionsMing-Lung Yu, Chao-Hung Hung, Yi-Hsiang Huang, et al.
Journal of Medical Virology|May 15, 2024
Four weeks of off-treatment follow-up is sufficient to determine virologic responses at off-treatment week 12 in patients with hepatitis C virus infection receiving fixed-dose pangenotypic direct-acting antiviralsChen-Hua Liu, Yu-Ping Chang, Ji-Yuh Lee, et al.
Journal of Gastroenterology|April 13, 2024
Dynamic change of metabolic dysfunction-associated steatotic liver disease in patients with hepatitis C virus infection after achieving sustained virologic response with direct-acting antiviralsChen-Hua Liu, Yu-Ping Chang, Yu-Jen Fang, et al.
Scientific Reports|May 13, 2017
Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosisTung-Hung Su, Chung-Wai Shiau, Ping Jao, et al.
Hepatology International|July 24, 2015
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 updateYun-Fan Liaw, Jia-Horng Kao, Teerha Piratvisuth, et al.
Journal of Gastroenterology and Hepatology|November 14, 2025
Predictive Value of Serum Mac-2 Binding Protein Glycosylation Isomer for Hepatic Fibrosis in Hepatitis C Virus-Infected Patients With Metabolic Dysfunction-Associated Steatotic Liver DiseaseYun-Chu Chen, Yu-Ping Chang, Ji-Yuh Lee, et al.
Journal of Medical Virology|January 15, 2026
Effect of Glycated Hemoglobin Levels on Serum Mac-2 Binding Protein Glycosylation Isomer in the Diagnosis of Hepatitis C-Virus Related Hepatic FibrosisYu-Ping Chang, Yun-Chu Chen, Ji-Yuh Lee, et al.
Open Forum Infectious Diseases|August 5, 2022
Hepatitis C Virus Reinfection in People With HIV in Taiwan After Achieving Sustained Virologic Response With Antiviral Treatment: The RECUR StudyChen-Hua Liu, Hsin-Yun Sun, Cheng-Yuan Peng, et al.
Gastroenterology|June 9, 2016
Long-term Effects of Hepatitis B Immunization of Infants in Preventing Liver CancerMei-Hwei Chang, San-Lin You, Chien-Jen Chen, et al.
Journal of Hepatology|March 24, 2009
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosageChun-Jen Liu, Po-Huang Lee, Deng-Yn Lin, et al.
Pageof 37

Showing results (301-310 of 367) with videos related to

Sort By:
Pageof 37
Journal of the Formosan Medical Association = Taiwan Yi Zhi|December 12, 2018
Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutionsMing-Lung Yu, Chao-Hung Hung, Yi-Hsiang Huang, et al.
Journal of Medical Virology|May 15, 2024
Four weeks of off-treatment follow-up is sufficient to determine virologic responses at off-treatment week 12 in patients with hepatitis C virus infection receiving fixed-dose pangenotypic direct-acting antiviralsChen-Hua Liu, Yu-Ping Chang, Ji-Yuh Lee, et al.
Journal of Gastroenterology|April 13, 2024
Dynamic change of metabolic dysfunction-associated steatotic liver disease in patients with hepatitis C virus infection after achieving sustained virologic response with direct-acting antiviralsChen-Hua Liu, Yu-Ping Chang, Yu-Jen Fang, et al.
Scientific Reports|May 13, 2017
Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosisTung-Hung Su, Chung-Wai Shiau, Ping Jao, et al.
Hepatology International|July 24, 2015
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 updateYun-Fan Liaw, Jia-Horng Kao, Teerha Piratvisuth, et al.
Journal of Gastroenterology and Hepatology|November 14, 2025
Predictive Value of Serum Mac-2 Binding Protein Glycosylation Isomer for Hepatic Fibrosis in Hepatitis C Virus-Infected Patients With Metabolic Dysfunction-Associated Steatotic Liver DiseaseYun-Chu Chen, Yu-Ping Chang, Ji-Yuh Lee, et al.
Journal of Medical Virology|January 15, 2026
Effect of Glycated Hemoglobin Levels on Serum Mac-2 Binding Protein Glycosylation Isomer in the Diagnosis of Hepatitis C-Virus Related Hepatic FibrosisYu-Ping Chang, Yun-Chu Chen, Ji-Yuh Lee, et al.
Open Forum Infectious Diseases|August 5, 2022
Hepatitis C Virus Reinfection in People With HIV in Taiwan After Achieving Sustained Virologic Response With Antiviral Treatment: The RECUR StudyChen-Hua Liu, Hsin-Yun Sun, Cheng-Yuan Peng, et al.
Gastroenterology|June 9, 2016
Long-term Effects of Hepatitis B Immunization of Infants in Preventing Liver CancerMei-Hwei Chang, San-Lin You, Chien-Jen Chen, et al.
Journal of Hepatology|March 24, 2009
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosageChun-Jen Liu, Po-Huang Lee, Deng-Yn Lin, et al.
Pageof 37